Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Ozurdex Endophthalmitis Cohort trial is studying endophthalmitis, a serious eye condition that can occur after receiving an OZURDEX implant, which is a treatment for certain eye diseases. The goal of the study is to understand how different treatments can impact patients' recovery over a year. This study is currently looking for participants who have developed endophthalmitis within two months after receiving an OZURDEX injection.
To be eligible, you must have had the OZURDEX injection and then developed this eye infection. However, if you had any other eye surgery between the injection and the infection, you would not be able to participate. If you choose to join the trial, you can expect to receive close monitoring and care to help assess your condition and the effectiveness of the treatments being studied. This trial is open to all adults, regardless of age or gender, and aims to improve understanding and outcomes for those affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient who had endophtalmitis following an OZURDEX implant injection within 2 months
- Exclusion Criteria:
- • Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Thibaud GARCIN, MD PhD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported